Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

January 11, 2024 updated by: AiCuris Anti-infective Cures AG

A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).

Study Overview

Status

Recruiting

Conditions

Detailed Description

The trial comprises 5 Parts, Part A, B, C, D, E and F.

Part A and Part B (Phase 2) have been finalised.

  • Part A is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety in subjects with ACV-resistant mucocutaneous HSV infection, treated with oral pritelivir or intravenous foscarnet.
  • Part B is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-resistant-mucocutaneous HSV and who either:

    1. present with foscarnet-resistance/intolerance, or
    2. developed foscarnet resistance/intolerance during treatment in Part A (no improvement after at least 5 days of foscarnet therapy or intolerance to foscarnet requiring cessation of foscarnet treatment).

      Parts C, D, E and F (Phase 3).

  • Part C is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety of oral pritelivir in subjects with acyclovir resistent (ACV-R) mucocutaneous HSV episodes. Subjects with ACV-R mucocutaneous HSV infection will be randomized 1:1 to receive either oral pritelivir or Investigator's Choice.

This trial part is designed to show superiority of pritelivir against Investigator's Choice in obtaining clinical cure, ie, number of subjects with all lesions healed within 28 days.

  • Part D is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either:

    1. present with iv foscarnet resistance/intolerance already at Screening for inclusion, or
    2. developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment). Part D has been closed in June 2022.
  • Part E is an open-label, multi-center design to assess the safety and efficacy of pritelivir in subjects with acyclovir susceptible (ACV-S) mucocutaneous HSV episodes, (Part E is not being conducted in Germany).
  • Part F is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either:

    1. present with iv foscarnet resistance/intolerance already at Screening for inclusion, or
    2. developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment).
    3. cannot be enrolled into Part D anymore because enrollment into Part D has been completed.

Dosing of trial medication:

Pritelivir oral tablet as single daily doses of 100 mg (following a loading dose of 400 mg as first dose)

Comparator per investigator's choice (provided the drug listed below is nationally approved):

Foscarnet intermittent infusions of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours (to be adjusted in case of renal impairment) for a minimum of 1 hour duration, or Cidofovir iv infusion of 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical treatment, applied 2 to 4 times daily, or Imiquimod 5% topical treatment, 3 times per week.

Duration of treatment:

Until all mucocutaneous HSV lesions are healed or up to 28 days, whichever is earlier.

A prolongation up to a maximum of 42 days may be possible depending on the clinical progress.

Study Type

Interventional

Enrollment (Estimated)

153

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Córdoba, Argentina, 5000
      • Córdoba, Argentina, 5000
      • La Plata, Argentina, CP 1900
        • Recruiting
        • Instituto FIDES
        • Contact:
      • Parkville, Australia, 3050
        • Recruiting
        • Melbourne Health - Royal Melbourne Hospital
        • Contact:
      • Westmead, Australia, 2145
        • Recruiting
        • Westmead Hospital, Centre for Infectious Disease and Microbiology
        • Contact:
      • Brussels, Belgium, B1000
        • Recruiting
        • Centre Hospitalier Universitaire Saint Pierre
        • Contact:
      • Roeselare, Belgium, 8800
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
      • Limoges, France, 87042
      • Nantes, France, 44093
      • Paris, France, 75010
        • Recruiting
        • Hôpital Saint Louis - AP-HP
        • Contact:
      • Paris, France, 75015
        • Recruiting
        • AP-HP Hopital Necker-Enfants Malades
        • Contact:
      • Paris, France, 75018
        • Recruiting
        • AP-HP Hopital Bichat - Claude Bernard
        • Contact:
      • Tbilisi, Georgia, 0159
        • Recruiting
        • LLC Diakor
        • Contact:
      • Tbilisi, Georgia, 0168
      • Tbilisi, Georgia, 0186
        • Recruiting
        • Multiprofile Clinic Consilium Medulla LTD
        • Contact:
      • Athens, Greece, 11527
        • Recruiting
        • General Hospital of Athens - Laiko
        • Contact:
      • Heraklion, Greece, 71110
        • Recruiting
        • Regional University General Hospital of Heraklion
        • Contact:
      • Calabria, Italy, 89133
        • Recruiting
        • Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
        • Contact:
      • Milano, Italy, 20122
        • Recruiting
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
        • Contact:
      • Pavia, Italy, 27100
      • Distrito Federal, Mexico, 03720
        • Recruiting
        • Centro de Investigación Clínica Gramel S.C.
        • Contact:
      • Durango, Mexico, 34000
        • Recruiting
        • Instituto de Investigaciones Aplicadas A La Neurociencia A.C
        • Contact:
      • Guadalajara, Mexico, 44160
        • Recruiting
        • Centro de Investigacion Farmaceutica Especializado de Occidente S.C.
        • Contact:
      • Monterrey, Mexico, 64718
      • Veracruz, Mexico, 91910
        • Recruiting
        • Arke SMO S.A. de C.V.
        • Contact:
      • Genève, Switzerland, 1205
      • Zuerich, Switzerland, 8091
      • London, United Kingdom, WC1E 6BT
        • Recruiting
        • Research Department of Haematology, UCL Cancer Institute
        • Contact:
      • Newcastle Upon Tyne, United Kingdom, NE7 7DN
        • Recruiting
        • Freeman Hospital
        • Contact:
    • Alabama
      • Birmingham, Alabama, United States, 35205
        • Recruiting
        • University of Alabama at Birmingham
        • Contact:
    • Arizona
      • Tucson, Arizona, United States, 85724
        • Recruiting
        • University Arizona - Department of Medicine Arizona Health Sciences Center
        • Contact:
    • California
      • Duarte, California, United States, 91010
        • Recruiting
        • City of Hope
        • Contact:
      • Los Angeles, California, United States, 90048
      • Sacramento, California, United States, 95817
        • Recruiting
        • University of California, Division of Infectious Diseases
        • Contact:
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Recruiting
        • Yale University School of Medicine - Infectious Diseases
        • Contact:
    • Florida
      • DeLand, Florida, United States, 32720
        • Recruiting
        • Midland Florida Clinical Research Center, LLC
        • Contact:
      • Fort Pierce, Florida, United States, 34982
        • Recruiting
        • Midway Immunology and Research Center (MIRC)
        • Contact:
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • University of Florida (UF) - Division of Infectious Disease
        • Contact:
      • Miami, Florida, United States, 33176
        • Recruiting
        • Links Clinical Trials
        • Contact:
      • Miami, Florida, United States, 33175
    • Georgia
      • Atlanta, Georgia, United States, 30308
        • Recruiting
        • Emory Hospital Midtown Infectious Disease Clinic
        • Contact:
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • Department of Medicine J. H. Stroger Hospital of Cook County
        • Contact:
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70809
        • Recruiting
        • LSU Health Baton Rouge Pulmonary Clinic
        • Contact:
      • New Orleans, Louisiana, United States, 70112
        • Recruiting
        • Tulane University - School of Medicine
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21205
        • Recruiting
        • Johns Hopkins University School of Medicine
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
    • Nebraska
      • Omaha, Nebraska, United States, 68198
        • Recruiting
        • University of Nebraska Medical Center
        • Contact:
    • New York
      • New York, New York, United States, 10021
        • Recruiting
        • David H. Koch Center at Memorial Sloan Kettering Cancer Center
        • Contact:
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27157
        • Recruiting
        • Atrium Health Wake Forest Baptist
        • Contact:
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • Cincinnati Children's Hospital Medical Center
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15232
        • Recruiting
        • University of Pittsburgh Medical Center
        • Contact:
    • Texas
      • Houston, Texas, United States, 77030-4009
        • Recruiting
        • MD Anderson Cancer Center
        • Contact:
    • Washington
      • Seattle, Washington, United States, 98109
        • Recruiting
        • Fred Hutchinson Cancer Research Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Part C inclusion criteria

  1. Immunocompromised men and women of any ethnic group aged ≥16 years.

    In Canada, Germany, Belgium:

    Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged >18 years.

  2. ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir.
  3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy.
  4. Willingness to use highly effective birth control.
  5. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form.
  6. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1.
  7. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany).

Part D and F inclusion criteria

All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:

2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment.

Subjects will be able to enter Part F only after closure of enrollment in Part D.

Part E inclusion (Part E is not being conducted in Germany)

All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:

2. Recurrent mucocutaneous HSV infection considered ACV-S.

Part C exclusion criteria

  1. Known resistance/intolerance to pritelivir or any of the excipients.
  2. Previous treatment in PRIOH-1.
  3. Baseline safety laboratory abnormalities.
  4. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.
  5. Hemodialysis for any indication and ESRD (eGFR <15 mL/min; stage 5 CKD)
  6. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases.
  7. Abnormalities in hematological, clinical chemical or any other laboratory variables.
  8. Not able to communicate meaningfully with the Investigator and site staff.
  9. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.
  10. Any other important local condition.
  11. Pregnant and/or breastfeeding women.
  12. Having received an investigational drug in an investigational drug trial unter certain conditions.

    Part D (complete) exclusion criteria

    All exclusion criteria as for Part C, except criterion 12, which is replaced by:

  13. Having received an investigational drug in an investigational trial within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial.

Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted.

Part E exclusion criteria (Part E is not being conducted in Germany)

All exclusion criteria in Part E are identical to those in Part C with the addition of:

13. Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir.

Part F exclusion criteria All exclusion criteria for Part D plus 13. Part D open for enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part C, Pritelivir
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
100 mg oral tablets
Experimental: Part D, Pritelivir
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
100 mg oral tablets
Experimental: Part E, Pritelivir
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
100 mg oral tablets
Experimental: Part F, Pritelivir
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
100 mg oral tablets
Active Comparator: Part C,

Investigator's Choice:

Foscarnet iv, 40 mg/kg tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg body weight given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, topically applied 3 times per week, for up to 28 days and potential prolongation for up to additional 14 days.

Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
Other Names:
  • Foscarnet or Cidofovir or Imiquimod

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy measured by cure rate
Time Frame: Up to a maximum of 28 days
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 28 days relative to the total number of subjects treated with trial medication in the respective treatment group.
Up to a maximum of 28 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy measured by cure rate
Time Frame: Up to a maximum of 42 days
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 42 days relative to the total number of subjects treated with trial medication in the respective treatment group.
Up to a maximum of 42 days
Efficacy measured by time to lesion healing
Time Frame: Up to a maximum of 42 days
Time to lesion healing, defined as complete epithelization of the mucocutaneous HSV lesion(s) within the treatment period and no appearance of new lesions, as assessed by the Investigator.
Up to a maximum of 42 days
Efficacy measured by recurrence rate
Time Frame: At 2 months following post treatment visit, from randomization up to a maximum of 108 days
Recurrence rate at 2 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
At 2 months following post treatment visit, from randomization up to a maximum of 108 days
Efficacy measured by recurrence rate
Time Frame: At 3 months following post treatment visit, from randomization up to a maximum of 139 days
Recurrence rate at 3 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
At 3 months following post treatment visit, from randomization up to a maximum of 139 days
Efficacy measured by pain rate
Time Frame: Up to a maximum of 42 days
Number of days with pain at lesion site relative to the total number of days with analyzable pain data through daily subject self-reporting
Up to a maximum of 42 days
Efficacy measured by time to pain cessation at site of lesion
Time Frame: Up to a maximum of 42 days
Starting at first dose of trial medication until pain is no longer reported by the subject (date and time)
Up to a maximum of 42 days
Efficacy measured by average pain score
Time Frame: Up to a maximum of 42 days
Using a single-dimensional scale assessing pain intensity through daily subject self-reporting
Up to a maximum of 42 days
Efficacy measured by clinical shedding rate
Time Frame: From date of randomization until the date of first documented healing, assessed up to a maximum of 42 days
Number of HSV positive swabs per subject relative to the total number of swabs collected per subject from lesion swabs taken from HSV lesion(s)
From date of randomization until the date of first documented healing, assessed up to a maximum of 42 days
Efficacy measured by time to cessation of shedding
Time Frame: Up to a maximum of 42 days
Number of days until swabs taken are negative
Up to a maximum of 42 days
Efficacy measured by mean log number of HSV DNA copies
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Mean log number of HSV DNA copies on HSV DNA positive swabs from lesion(s) as detected by quantitative real-time PCR (polymerase chain reaction).
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Efficacy measured by resistance to trial medication
Time Frame: From date of randomization until the date of post treatment visit, assessed up to a maximum of 73 days
Resistance to trial medication for lesions not healed within the treatment period or newly appeared lesions under treatment before or at the PoTV.
From date of randomization until the date of post treatment visit, assessed up to a maximum of 73 days
Safety measured by number of subjects developing chronic kidney disease
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Chronic kidney disease
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing chronic kidney disease
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Chronic kidney disease
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing renal impairment
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Renal impairment
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by adverse events
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of Adverse Events
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by haematology
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of abnormal hematologic laboratory test results
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by lymphadenopathy
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of lymphadenopathy measured by physical examination
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by CRP (C reactive protein )
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of CRP increase
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by cutaneous adverse events
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of cutaneous adverse events by physical examination
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by (a)PTT (partial thromboplastin time)
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Incidence of (a)PTT increase
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing acute Kidney Injury
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Acute Kidney Injury (AKI) stage >1 of KDIGO (Kidney Disease: Improving Global Outcome) criteria (increase in serum creatinine by 2.0 to 2.9 times compared to baseline or urine output <0.5 mL/kg/h for >12 hours)
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing electrolyte abnormality
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
All abnormal values
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing seizures
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
All seizures
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by percentage of subjects developing anemia
Time Frame: From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Haemoglobin measurement
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Safety measured by discontinuation rate
Time Frame: Up to a maximum of 42 days
Number of subjects discontinuing pritelivir or 'Inverstigator's Choice' due to AE(s) or intolerance relative to the total number of subjects treated with pritelivir or foscarnet, respectively
Up to a maximum of 42 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 8, 2017

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

April 1, 2025

Study Registration Dates

First Submitted

March 3, 2017

First Submitted That Met QC Criteria

March 3, 2017

First Posted (Actual)

March 8, 2017

Study Record Updates

Last Update Posted (Actual)

January 12, 2024

Last Update Submitted That Met QC Criteria

January 11, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HSV Infection

Clinical Trials on Pritelivir

3
Subscribe